O	0	8	Vascular	Vascular	JJ	B-NP
O	9	20	endothelial	endothelial	JJ	I-NP
O	21	27	growth	growth	NN	I-NP
O	28	34	factor	factor	NN	I-NP
O	34	35	-	-	HYPH	O
O	35	36	B	B	NN	B-NP
O	37	40	and	and	CC	O
O	41	49	vascular	vascular	JJ	B-NP
O	50	61	endothelial	endothelial	JJ	I-NP
O	62	68	growth	growth	NN	I-NP
O	69	75	factor	factor	NN	I-NP
O	75	76	-	-	HYPH	B-NP
O	76	77	C	C	NN	I-NP
O	78	88	expression	expression	NN	I-NP
O	89	91	in	in	IN	B-PP
B-Cancer	92	97	renal	renal	JJ	B-NP
I-Cancer	98	102	cell	cell	NN	I-NP
I-Cancer	103	113	carcinomas	carcinoma	NNS	I-NP
O	113	114	:	:	:	O
O	115	125	regulation	regulation	NN	B-NP
O	126	128	by	by	IN	B-PP
O	129	132	the	the	DT	B-NP
O	133	136	von	von	NNP	I-NP
O	137	143	Hippel	Hippel	NNP	I-NP
O	143	144	-	-	HYPH	I-NP
O	144	150	Lindau	Lindau	NNP	I-NP
O	151	155	gene	gene	NN	I-NP
O	156	159	and	and	CC	I-NP
O	160	167	hypoxia	hypoxia	NN	I-NP
O	167	168	.	.	.	O

O	169	181	Angiogenesis	Angiogenesis	NN	B-NP
O	182	184	is	be	VBZ	B-VP
O	185	194	essential	essential	JJ	B-ADJP
O	195	198	for	for	IN	B-PP
B-Cancer	199	204	tumor	tumor	NN	B-NP
O	205	211	growth	growth	NN	I-NP
O	212	215	and	and	CC	I-NP
O	216	226	metastasis	metastasis	NN	I-NP
O	226	227	.	.	.	O

O	228	230	It	It	PRP	B-NP
O	231	233	is	be	VBZ	B-VP
O	234	243	regulated	regulate	VBN	I-VP
O	244	246	by	by	IN	B-PP
O	247	255	numerous	numerous	JJ	B-NP
O	256	266	angiogenic	angiogenic	JJ	I-NP
O	267	274	factors	factor	NNS	I-NP
O	274	275	,	,	,	O
O	276	279	one	one	CD	B-NP
O	280	282	of	of	IN	B-PP
O	283	286	the	the	DT	B-NP
O	287	291	most	most	RBS	I-NP
O	292	301	important	important	JJ	I-NP
O	302	307	being	be	VBG	B-VP
O	308	316	vascular	vascular	JJ	B-NP
O	317	328	endothelial	endothelial	JJ	I-NP
O	329	335	growth	growth	NN	I-NP
O	336	342	factor	factor	NN	I-NP
O	343	344	(	(	(	O
O	344	348	VEGF	VEGF	NN	B-NP
O	348	349	)	)	)	O
O	349	350	.	.	.	O

O	351	359	Recently	Recently	RB	B-NP
O	360	364	VEGF	VEGF	NN	I-NP
O	364	365	-	-	HYPH	I-NP
O	365	366	B	B	NN	I-NP
O	367	370	and	and	CC	I-NP
O	371	375	VEGF	VEGF	NN	I-NP
O	375	376	-	-	HYPH	I-NP
O	376	377	C	C	NN	I-NP
O	377	378	,	,	,	O
O	379	382	two	two	CD	B-NP
O	383	386	new	new	JJ	I-NP
O	387	391	VEGF	VEGF	NN	I-NP
O	392	398	family	family	NN	I-NP
O	399	406	members	member	NNS	I-NP
O	406	407	,	,	,	O
O	408	412	have	have	VBP	B-VP
O	413	417	been	be	VBN	I-VP
O	418	428	identified	identify	VBN	I-VP
O	429	433	that	that	WDT	B-NP
O	434	438	bind	bind	VBP	B-VP
O	439	441	to	to	TO	B-PP
O	442	445	the	the	DT	B-NP
O	446	454	tyrosine	tyrosine	NN	I-NP
O	455	461	kinase	kinase	NN	I-NP
O	462	471	receptors	receptor	NNS	I-NP
O	472	475	flt	flt	NN	I-NP
O	475	476	-	-	HYPH	B-NP
O	476	477	1	1	CD	I-NP
O	478	479	(	(	(	O
O	479	485	VEGFR1	VEGFR1	NN	B-NP
O	485	486	)	)	)	O
O	486	487	,	,	,	O
O	488	491	KDR	KDR	NN	B-NP
O	492	493	(	(	(	O
O	493	499	VEGFR2	VEGFR2	NN	B-NP
O	499	500	)	)	)	O
O	500	501	,	,	,	O
O	502	505	and	and	CC	O
O	506	509	flt	flt	NN	B-NP
O	509	510	-	-	HYPH	O
O	510	511	4	4	CD	B-NP
O	512	513	(	(	(	O
O	513	519	VEGFR3	VEGFR3	NN	B-NP
O	519	520	)	)	)	O
O	520	521	.	.	.	O

O	522	530	Although	Although	IN	B-SBAR
O	531	534	the	the	DT	B-NP
O	535	545	importance	importance	NN	I-NP
O	546	548	of	of	IN	B-PP
O	549	553	VEGF	VEGF	NN	B-NP
O	553	554	-	-	HYPH	B-NP
O	554	555	A	A	NN	I-NP
O	556	559	has	have	VBZ	B-VP
O	560	564	been	be	VBN	I-VP
O	565	570	shown	show	VBN	I-VP
O	571	573	in	in	IN	B-PP
B-Cancer	574	579	renal	renal	JJ	B-NP
I-Cancer	580	590	carcinomas	carcinoma	NNS	I-NP
O	590	591	,	,	,	O
O	592	595	the	the	DT	B-NP
O	596	608	contribution	contribution	NN	I-NP
O	609	611	of	of	IN	B-PP
O	612	617	these	these	DT	B-NP
O	618	621	new	new	JJ	I-NP
O	622	629	ligands	ligand	NNS	I-NP
O	630	632	in	in	IN	B-PP
B-Cancer	633	639	kidney	kidney	NN	B-NP
I-Cancer	640	646	tumors	tumor	NNS	I-NP
O	647	649	is	be	VBZ	B-VP
O	650	653	not	not	RB	O
O	654	659	clear	clear	JJ	B-ADJP
O	659	660	.	.	.	O

O	661	663	We	We	PRP	B-NP
O	664	668	have	have	VBP	B-VP
O	668	669	,	,	,	O
O	670	679	therefore	therefore	RB	B-ADVP
O	679	680	,	,	,	O
O	681	689	measured	measure	VBD	B-VP
O	690	693	the	the	DT	B-NP
O	694	698	mRNA	mRNA	NN	I-NP
O	699	704	level	level	NN	I-NP
O	705	707	of	of	IN	B-PP
O	708	712	VEGF	VEGF	NN	B-NP
O	712	713	-	-	HYPH	B-NP
O	713	714	B	B	NN	I-NP
O	715	718	and	and	CC	I-NP
O	719	723	VEGF	VEGF	NN	I-NP
O	723	724	-	-	HYPH	I-NP
O	724	725	C	C	NN	I-NP
O	726	734	together	together	RB	B-ADVP
O	735	739	with	with	IN	B-PP
O	740	745	their	their	PRP$	B-NP
O	746	755	receptors	receptor	NNS	I-NP
O	756	758	by	by	IN	B-PP
O	759	764	RNase	RNase	NN	B-NP
O	765	775	protection	protection	NN	I-NP
O	776	781	assay	assay	NN	I-NP
O	782	783	(	(	(	O
O	783	786	RPA	RPA	NN	B-NP
O	786	787	)	)	)	O
O	788	790	in	in	IN	B-PP
O	791	793	26	26	CD	B-NP
O	794	800	normal	normal	JJ	I-NP
B-Multi-tissue_structure	801	807	kidney	kidney	NN	I-NP
I-Multi-tissue_structure	808	815	samples	sample	NNS	I-NP
O	816	819	and	and	CC	O
O	820	822	45	45	CD	B-NP
B-Cancer	823	828	renal	renal	JJ	I-NP
I-Cancer	829	833	cell	cell	NN	I-NP
I-Cancer	834	841	cancers	cancer	NNS	I-NP
O	841	842	.	.	.	O

O	843	845	We	We	PRP	B-NP
O	846	854	observed	observe	VBD	B-VP
O	855	856	a	a	DT	B-NP
O	857	868	significant	significant	JJ	I-NP
O	869	871	up	up	RB	B-ADVP
O	871	872	-	-	HYPH	O
O	872	882	regulation	regulation	NN	B-NP
O	883	885	of	of	IN	B-PP
O	886	890	VEGF	VEGF	NN	B-NP
O	890	891	-	-	HYPH	O
O	891	892	B	B	NN	B-NP
O	893	894	(	(	(	O
O	894	895	P	P	NN	B-NP
O	896	897	=	=	SYM	B-VP
O	898	899	0	0	CD	B-NP
O	899	900	.	.	.	O
O	900	903	002	002	CD	B-NP
O	903	904	)	)	)	O
O	905	908	but	but	CC	B-NP
O	909	912	not	not	RB	I-NP
O	913	917	VEGF	VEGF	NN	I-NP
O	917	918	-	-	HYPH	O
O	918	919	C	C	NN	B-NP
O	920	921	(	(	(	O
O	921	922	P	P	NN	B-NP
O	923	924	=	=	SYM	B-VP
O	925	926	0	0	CD	B-NP
O	926	927	.	.	SYM	I-NP
O	927	928	3	3	CD	I-NP
O	928	929	)	)	)	O
O	930	932	in	in	IN	B-PP
B-Organ	933	943	neoplastic	neoplastic	JJ	B-NP
I-Organ	944	950	kidney	kidney	NN	I-NP
O	951	959	compared	compare	VBN	B-PP
O	960	964	with	with	IN	B-PP
O	965	971	normal	normal	JJ	B-NP
B-Tissue	972	979	tissues	tissue	NNS	I-NP
O	979	980	.	.	.	O

O	981	983	In	In	IN	B-PP
O	984	992	addition	addition	NN	B-NP
O	992	993	,	,	,	O
O	994	1002	although	although	IN	B-SBAR
O	1003	1007	VEGF	VEGF	NN	B-NP
O	1008	1017	receptors	receptor	NNS	I-NP
O	1018	1022	were	be	VBD	B-VP
O	1023	1029	higher	high	JJR	B-ADJP
O	1030	1032	in	in	IN	B-PP
B-Cancer	1033	1039	tumors	tumor	NNS	B-NP
O	1040	1044	than	than	IN	B-PP
O	1045	1051	normal	normal	JJ	B-NP
B-Organ	1052	1058	kidney	kidney	NN	I-NP
O	1058	1059	,	,	,	O
O	1060	1065	there	there	EX	B-NP
O	1066	1069	was	be	VBD	B-VP
O	1070	1071	a	a	DT	B-NP
O	1072	1083	significant	significant	JJ	I-NP
O	1084	1086	up	up	RB	B-ADVP
O	1086	1087	-	-	HYPH	O
O	1087	1097	regulation	regulation	NN	B-NP
O	1098	1100	of	of	IN	B-PP
O	1101	1105	only	only	JJ	B-NP
O	1106	1109	flt	flt	NN	I-NP
O	1109	1110	-	-	HYPH	B-NP
O	1110	1111	1	1	CD	I-NP
O	1112	1113	(	(	(	O
O	1113	1114	P	P	NN	B-NP
O	1115	1116	=	=	SYM	B-VP
O	1117	1118	0	0	CD	B-NP
O	1118	1119	.	.	.	O
O	1119	1122	003	003	CD	B-NP
O	1122	1123	)	)	)	O
O	1124	1127	but	but	CC	B-NP
O	1128	1131	not	not	RB	I-NP
O	1132	1135	KDR	KDR	NN	B-NP
O	1136	1137	(	(	(	O
O	1137	1138	P	P	NN	B-NP
O	1139	1140	=	=	SYM	B-VP
O	1141	1142	0	0	CD	B-NP
O	1142	1143	.	.	SYM	I-NP
O	1143	1145	12	12	CD	I-NP
O	1145	1146	)	)	)	O
O	1147	1149	or	or	CC	O
O	1150	1153	flt	flt	NN	B-NP
O	1153	1154	-	-	HYPH	O
O	1154	1155	4	4	CD	B-NP
O	1156	1157	(	(	(	O
O	1157	1158	P	P	NN	B-NP
O	1159	1160	=	=	SYM	B-VP
O	1161	1162	0	0	CD	B-NP
O	1162	1163	.	.	SYM	I-NP
O	1163	1165	09	09	CD	I-NP
O	1165	1166	)	)	)	O
O	1166	1167	.	.	.	O

O	1168	1173	There	There	EX	B-NP
O	1174	1177	was	be	VBD	B-VP
O	1178	1182	also	also	RB	B-ADVP
O	1183	1184	a	a	DT	B-NP
O	1185	1196	significant	significant	JJ	I-NP
O	1197	1208	correlation	correlation	NN	I-NP
O	1209	1216	between	between	IN	B-PP
O	1217	1221	VEGF	VEGF	NN	B-NP
O	1221	1222	-	-	HYPH	I-NP
O	1222	1223	C	C	NN	I-NP
O	1224	1227	and	and	CC	O
O	1228	1232	both	both	DT	B-NP
O	1233	1235	of	of	IN	B-PP
O	1236	1239	its	its	PRP$	B-NP
O	1240	1249	receptors	receptor	NNS	I-NP
O	1250	1253	flt	flt	NN	I-NP
O	1253	1254	-	-	HYPH	B-NP
O	1254	1255	4	4	CD	I-NP
O	1256	1257	(	(	(	O
O	1257	1258	P	P	NN	B-NP
O	1259	1260	=	=	SYM	B-VP
O	1261	1262	0	0	CD	B-NP
O	1262	1263	.	.	SYM	I-NP
O	1263	1266	006	006	CD	I-NP
O	1266	1267	)	)	)	O
O	1268	1271	and	and	CC	O
O	1272	1275	KDR	KDR	NN	B-NP
O	1276	1277	(	(	(	O
O	1277	1278	P	P	NN	B-NP
O	1279	1280	=	=	SYM	B-VP
O	1281	1282	0	0	CD	B-NP
O	1282	1283	.	.	.	O
O	1283	1285	03	03	CD	B-NP
O	1285	1286	)	)	)	O
O	1287	1290	but	but	CC	O
O	1291	1293	no	no	DT	B-NP
O	1294	1305	association	association	NN	I-NP
O	1306	1313	between	between	IN	B-PP
O	1314	1318	VEGF	VEGF	NN	B-NP
O	1318	1319	-	-	HYPH	I-NP
O	1319	1320	B	B	NN	I-NP
O	1321	1324	and	and	CC	O
O	1325	1328	its	its	PRP$	B-NP
O	1329	1337	receptor	receptor	NN	I-NP
O	1338	1341	flt	flt	NN	I-NP
O	1341	1342	-	-	HYPH	B-NP
O	1342	1343	1	1	CD	I-NP
O	1344	1345	(	(	(	O
O	1345	1346	P	P	NN	B-NP
O	1347	1348	=	=	SYM	B-VP
O	1349	1350	0	0	CD	B-NP
O	1350	1351	.	.	SYM	I-NP
O	1351	1353	23	23	CD	I-NP
O	1353	1354	)	)	)	O
O	1354	1355	.	.	.	O

O	1356	1357	A	A	DT	B-NP
O	1358	1369	significant	significant	JJ	I-NP
O	1370	1378	increase	increase	NN	I-NP
O	1379	1382	was	be	VBD	B-VP
O	1383	1391	observed	observe	VBN	I-VP
O	1392	1394	in	in	IN	B-PP
O	1395	1398	flt	flt	NN	B-NP
O	1398	1399	-	-	HYPH	B-NP
O	1399	1400	1	1	CD	I-NP
O	1401	1402	(	(	(	O
O	1402	1403	P	P	NN	B-NP
O	1405	1409	less	less	JJR	B-NP
O	1410	1414	than	than	IN	I-NP
O	1416	1417	0	0	CD	I-NP
O	1417	1418	.	.	.	I-NP
O	1418	1421	001	001	CD	I-NP
O	1421	1422	)	)	)	O
O	1422	1423	,	,	,	O
O	1424	1427	KDR	KDR	NN	B-NP
O	1428	1429	(	(	(	O
O	1429	1430	P	P	NN	B-NP
O	1431	1432	=	=	SYM	B-VP
O	1433	1434	0	0	CD	B-NP
O	1434	1435	.	.	.	O
O	1435	1437	02	02	CD	B-NP
O	1437	1438	)	)	)	O
O	1438	1439	,	,	,	O
O	1440	1443	and	and	CC	O
O	1444	1447	flt	flt	NN	B-NP
O	1447	1448	-	-	HYPH	O
O	1448	1449	4	4	CD	B-NP
O	1450	1451	(	(	(	O
O	1451	1452	P	P	NN	B-NP
O	1453	1454	=	=	SYM	B-VP
O	1455	1456	0	0	CD	B-NP
O	1456	1457	.	.	SYM	I-NP
O	1457	1459	01	01	CD	I-NP
O	1459	1460	)	)	)	O
O	1461	1464	but	but	CC	B-NP
O	1465	1468	not	not	RB	I-NP
O	1469	1473	VEGF	VEGF	NN	I-NP
O	1473	1474	-	-	HYPH	O
O	1474	1475	B	B	NN	B-NP
O	1476	1477	(	(	(	O
O	1477	1478	P	P	NN	B-NP
O	1479	1480	=	=	SYM	B-VP
O	1481	1482	0	0	CD	B-NP
O	1482	1483	.	.	SYM	I-NP
O	1483	1485	82	82	CD	I-NP
O	1485	1486	)	)	)	O
O	1487	1489	or	or	CC	O
O	1490	1494	VEGF	VEGF	NN	B-NP
O	1494	1495	-	-	HYPH	O
O	1495	1496	C	C	NN	B-NP
O	1497	1498	(	(	(	O
O	1498	1499	P	P	NN	B-NP
O	1500	1501	=	=	SYM	B-VP
O	1502	1503	0	0	CD	B-NP
O	1503	1504	.	.	SYM	I-NP
O	1504	1506	52	52	CD	I-NP
O	1506	1507	)	)	)	O
O	1508	1518	expression	expression	NN	B-NP
O	1519	1521	in	in	IN	B-PP
B-Cell	1522	1527	clear	clear	JJ	B-NP
I-Cell	1528	1532	cell	cell	NN	I-NP
O	1533	1541	compared	compare	VBN	B-PP
O	1542	1546	with	with	IN	B-PP
B-Cancer	1547	1557	chromophil	chromophil	NN	B-NP
I-Cancer	1558	1559	(	(	(	O
I-Cancer	1559	1568	papillary	papillary	JJ	O
I-Cancer	1568	1569	)	)	)	O
I-Cancer	1570	1580	carcinomas	carcinoma	NNS	B-NP
O	1580	1581	.	.	.	O

O	1582	1584	No	No	DT	B-NP
O	1585	1596	significant	significant	JJ	I-NP
O	1597	1608	association	association	NN	I-NP
O	1609	1612	was	be	VBD	B-VP
O	1613	1625	demonstrated	demonstrate	VBN	I-VP
O	1626	1633	between	between	IN	B-PP
O	1634	1638	VEGF	VEGF	NN	B-NP
O	1638	1639	-	-	HYPH	I-NP
O	1639	1640	B	B	NN	I-NP
O	1640	1641	,	,	,	O
O	1642	1646	VEGF	VEGF	NN	B-NP
O	1646	1647	-	-	HYPH	I-NP
O	1647	1648	C	C	NN	I-NP
O	1648	1649	,	,	,	O
O	1650	1653	flt	flt	NN	B-NP
O	1653	1654	-	-	HYPH	B-NP
O	1654	1655	1	1	CD	I-NP
O	1655	1656	,	,	,	O
O	1657	1660	KDR	KDR	NN	B-NP
O	1660	1661	,	,	,	O
O	1662	1665	and	and	CC	O
O	1666	1669	flt	flt	NN	B-NP
O	1669	1670	-	-	HYPH	O
O	1670	1671	4	4	CD	B-NP
O	1672	1676	with	with	IN	B-PP
O	1677	1684	patient	patient	NN	B-NP
O	1685	1688	sex	sex	NN	I-NP
O	1688	1689	,	,	,	O
O	1690	1697	patient	patient	NN	B-NP
O	1698	1701	age	age	NN	I-NP
O	1701	1702	,	,	,	O
O	1703	1705	or	or	CC	O
B-Cancer	1706	1711	tumor	tumor	NN	B-NP
O	1712	1716	size	size	NN	I-NP
O	1717	1718	(	(	(	O
O	1718	1719	P	P	NN	B-NP
O	1721	1728	greater	great	JJR	B-ADJP
O	1729	1733	than	than	IN	B-PP
O	1735	1736	0	0	CD	B-NP
O	1736	1737	.	.	.	O
O	1737	1739	05	05	CD	B-NP
O	1739	1740	)	)	)	O
O	1740	1741	.	.	.	O

O	1742	1745	The	The	DT	B-NP
O	1746	1752	effect	effect	NN	I-NP
O	1753	1755	of	of	IN	B-PP
O	1756	1759	von	von	NNP	B-NP
O	1760	1766	Hippel	Hippel	NNP	I-NP
O	1766	1767	-	-	HYPH	I-NP
O	1767	1773	Lindau	Lindau	NNP	I-NP
O	1774	1775	(	(	(	O
O	1775	1778	VHL	VHL	NNP	O
O	1778	1779	)	)	)	O
O	1780	1784	gene	gene	NN	B-NP
O	1785	1788	and	and	CC	I-NP
O	1789	1796	hypoxia	hypoxia	NN	I-NP
O	1797	1799	on	on	IN	B-PP
O	1800	1804	VEGF	VEGF	NN	B-NP
O	1804	1805	-	-	HYPH	I-NP
O	1805	1806	B	B	NN	I-NP
O	1807	1810	and	and	CC	I-NP
O	1811	1815	VEGF	VEGF	NN	I-NP
O	1815	1816	-	-	HYPH	I-NP
O	1816	1817	C	C	NN	I-NP
O	1818	1828	expression	expression	NN	I-NP
O	1829	1831	in	in	IN	B-PP
O	1832	1835	the	the	DT	B-NP
B-Cell	1836	1841	renal	renal	JJ	I-NP
I-Cell	1842	1851	carcinoma	carcinoma	NN	I-NP
I-Cell	1852	1856	cell	cell	NN	I-NP
I-Cell	1857	1861	line	line	NN	I-NP
I-Cell	1862	1865	786	786	CD	I-NP
I-Cell	1865	1866	-	-	HYPH	I-NP
I-Cell	1866	1867	0	0	CD	I-NP
O	1868	1879	transfected	transfecte	VBN	B-VP
O	1880	1884	with	with	IN	B-PP
O	1885	1889	wild	wild	JJ	B-NP
O	1889	1890	-	-	HYPH	I-NP
O	1890	1894	type	type	NN	I-NP
O	1895	1898	and	and	CC	I-NP
O	1899	1905	mutant	mutant	NN	I-NP
O	1906	1909	VHL	VHL	NN	I-NP
O	1910	1913	was	be	VBD	B-VP
O	1914	1924	determined	determine	VBN	I-VP
O	1925	1927	by	by	IN	B-PP
O	1928	1935	growing	grow	VBG	B-NP
B-Cell	1936	1941	cells	cell	NNS	I-NP
O	1942	1947	under	under	IN	B-PP
O	1948	1950	21	21	CD	B-NP
O	1950	1951	%	%	NN	I-NP
O	1952	1954	O2	O2	NN	I-NP
O	1954	1955	-	-	HYPH	B-ADJP
O	1956	1959	and	and	CC	O
O	1960	1961	0	0	CD	B-NP
O	1961	1962	.	.	.	O
O	1962	1963	1	1	CD	B-NP
O	1963	1964	%	%	NN	I-NP
O	1965	1967	O2	O2	NN	I-NP
O	1967	1968	.	.	.	O

O	1969	1971	In	In	IN	B-PP
B-Cell	1972	1976	wild	wild	JJ	B-NP
I-Cell	1976	1977	-	-	HYPH	I-NP
I-Cell	1977	1981	type	type	NN	I-NP
I-Cell	1982	1985	VHL	VHL	NN	I-NP
I-Cell	1986	1991	cells	cell	NNS	I-NP
O	1991	1992	,	,	,	O
O	1993	2000	whereas	whereas	IN	O
O	2001	2005	VEGF	VEGF	NN	B-NP
O	2005	2006	-	-	HYPH	I-NP
O	2006	2007	A	A	NN	I-NP
O	2008	2011	was	be	VBD	B-VP
O	2012	2025	significantly	significantly	RB	B-ADVP
O	2026	2028	up	up	RB	B-ADVP
O	2028	2029	-	-	HYPH	B-NP
O	2029	2038	regulated	regulate	VBN	B-VP
O	2039	2044	under	under	IN	B-PP
O	2045	2052	hypoxic	hypoxic	JJ	B-ADJP
O	2053	2061	compared	compare	VBN	B-PP
O	2062	2066	with	with	IN	B-PP
O	2067	2075	normoxic	normoxic	JJ	B-NP
O	2076	2086	conditions	condition	NNS	I-NP
O	2087	2088	(	(	(	O
O	2088	2089	P	P	NN	B-NP
O	2091	2095	less	less	JJR	B-NP
O	2096	2100	than	than	IN	I-NP
O	2102	2103	0	0	CD	I-NP
O	2103	2104	.	.	.	I-NP
O	2104	2107	001	001	CD	I-NP
O	2107	2108	)	)	)	O
O	2108	2109	,	,	,	O
O	2110	2120	expression	expression	NN	B-NP
O	2121	2123	of	of	IN	B-PP
O	2124	2128	VEGF	VEGF	NN	B-NP
O	2128	2129	-	-	HYPH	B-NP
O	2129	2130	C	C	NN	I-NP
O	2131	2134	was	be	VBD	B-VP
O	2135	2142	reduced	reduce	VBN	I-VP
O	2143	2144	(	(	(	O
O	2144	2145	P	P	NN	B-NP
O	2147	2151	less	less	JJR	B-NP
O	2152	2156	than	than	IN	I-NP
O	2158	2159	0	0	CD	I-NP
O	2159	2160	.	.	.	I-NP
O	2160	2163	002	002	CD	I-NP
O	2163	2164	)	)	)	O
O	2164	2165	.	.	.	O

O	2166	2178	Nevertheless	Nevertheless	RB	B-ADVP
O	2178	2179	,	,	,	O
O	2180	2183	the	the	DT	B-NP
O	2184	2194	repression	repression	NN	I-NP
O	2195	2197	of	of	IN	B-PP
O	2198	2202	VEGF	VEGF	NN	B-NP
O	2202	2203	-	-	HYPH	B-NP
O	2203	2204	C	C	NN	I-NP
O	2205	2208	was	be	VBD	B-VP
O	2209	2213	lost	lose	VBN	I-VP
O	2214	2216	in	in	IN	B-PP
B-Cell	2217	2223	mutant	mutant	JJ	B-NP
I-Cell	2224	2227	VHL	VHL	NN	I-NP
I-Cell	2228	2232	cell	cell	NN	I-NP
I-Cell	2233	2238	lines	line	NNS	I-NP
O	2239	2244	under	under	IN	B-PP
O	2245	2252	hypoxia	hypoxia	NN	B-NP
O	2252	2253	.	.	.	O

O	2254	2256	In	In	IN	B-PP
O	2257	2265	contrast	contrast	NN	B-NP
O	2266	2270	VEGF	VEGF	NN	I-NP
O	2270	2271	-	-	HYPH	B-NP
O	2271	2272	B	B	NN	I-NP
O	2273	2276	was	be	VBD	B-VP
O	2277	2280	not	not	RB	I-VP
O	2281	2290	regulated	regulate	VBN	I-VP
O	2291	2293	by	by	IN	B-PP
O	2294	2297	VHL	VHL	NN	B-NP
O	2298	2305	despite	despite	IN	B-PP
O	2306	2311	clear	clear	JJ	B-ADJP
O	2312	2314	up	up	RB	B-ADVP
O	2314	2315	-	-	HYPH	B-NP
O	2315	2325	regulation	regulation	NN	I-NP
O	2326	2328	in	in	FW	B-ADVP
O	2329	2333	vivo	vivo	FW	I-ADVP
O	2333	2334	.	.	.	O

O	2335	2340	These	These	DT	B-NP
O	2341	2349	findings	finding	NNS	I-NP
O	2350	2358	strongly	strongly	RB	B-ADVP
O	2359	2366	support	support	VBP	B-VP
O	2367	2369	an	an	DT	B-NP
O	2370	2378	enhanced	enhance	VBN	I-NP
O	2379	2383	role	role	NN	I-NP
O	2384	2387	for	for	IN	B-PP
O	2388	2392	this	this	DT	B-NP
O	2393	2400	pathway	pathway	NN	I-NP
O	2401	2403	in	in	IN	B-PP
B-Cancer	2404	2409	clear	clear	JJ	B-NP
I-Cancer	2410	2414	cell	cell	NN	I-NP
I-Cancer	2415	2425	carcinomas	carcinoma	NNS	I-NP
O	2426	2428	by	by	IN	B-PP
O	2429	2439	regulating	regulate	VBG	B-VP
O	2440	2452	angiogenesis	angiogenesis	NN	B-NP
O	2453	2456	and	and	CC	O
O	2456	2457	/	/	SYM	B-NP
O	2457	2459	or	or	CC	O
O	2460	2477	lymphangiogenesis	lymphangiogenesis	NN	B-NP
O	2477	2478	.	.	.	O

O	2479	2482	The	The	DT	B-NP
O	2483	2488	study	study	NN	I-NP
O	2489	2494	shows	show	VBZ	B-VP
O	2495	2499	that	that	IN	B-SBAR
B-Cancer	2500	2505	clear	clear	JJ	B-NP
I-Cancer	2506	2510	cell	cell	NN	I-NP
I-Cancer	2511	2517	tumors	tumor	NNS	I-NP
O	2518	2521	are	be	VBP	B-VP
O	2522	2526	able	able	JJ	B-ADJP
O	2527	2529	to	to	TO	B-PP
O	2530	2532	up	up	RB	B-ADVP
O	2532	2533	-	-	HYPH	O
O	2533	2541	regulate	regulate	VB	B-VP
O	2542	2552	angiogenic	angiogenic	JJ	B-NP
O	2553	2559	growth	growth	NN	I-NP
O	2560	2566	factor	factor	NN	I-NP
O	2567	2576	receptors	receptor	NNS	I-NP
O	2577	2581	more	more	RBR	B-ADVP
O	2582	2593	efficiently	efficiently	RB	I-ADVP
O	2594	2598	than	than	IN	B-PP
B-Cancer	2599	2609	chromophil	chromophil	NN	B-NP
O	2610	2611	(	(	(	O
B-Cancer	2611	2620	papillary	papillary	JJ	B-ADVP
O	2620	2621	)	)	)	O
O	2621	2622	,	,	,	O
O	2623	2627	that	that	IN	B-SBAR
B-Cancer	2628	2633	clear	clear	JJ	B-NP
I-Cancer	2634	2638	cell	cell	NN	I-NP
I-Cancer	2639	2645	tumors	tumor	NNS	I-NP
O	2646	2649	can	can	MD	B-VP
O	2650	2653	use	use	VB	I-VP
O	2654	2662	pathways	pathway	NNS	B-NP
O	2663	2674	independent	independent	JJ	B-ADJP
O	2675	2677	of	of	IN	B-PP
O	2678	2681	VHL	VHL	NN	B-NP
O	2682	2684	to	to	TO	B-VP
O	2685	2693	regulate	regulate	VB	I-VP
O	2694	2706	angiogenesis	angiogenesis	NN	B-NP
O	2706	2707	,	,	,	O
O	2708	2711	and	and	CC	O
O	2712	2716	that	that	IN	B-SBAR
O	2717	2721	this	this	DT	B-NP
O	2722	2730	combined	combine	VBN	I-NP
O	2731	2741	regulation	regulation	NN	I-NP
O	2742	2745	may	may	MD	B-VP
O	2746	2753	account	account	VB	I-VP
O	2754	2757	for	for	IN	B-PP
O	2758	2763	their	their	PRP$	B-NP
O	2764	2768	more	more	RBR	I-NP
O	2769	2779	aggressive	aggressive	JJ	I-NP
O	2780	2789	phenotype	phenotype	NN	I-NP
O	2789	2790	,	,	,	O
O	2791	2796	which	which	WDT	B-NP
O	2797	2805	suggests	suggest	VBZ	B-VP
O	2806	2810	that	that	IN	B-SBAR
O	2811	2820	targeting	target	VBG	B-VP
O	2821	2827	VEGFR1	VEGFR1	NN	B-NP
O	2828	2829	(	(	(	O
O	2829	2832	flt	flt	NN	B-NP
O	2832	2833	-	-	HYPH	B-NP
O	2833	2834	l	l	NN	I-NP
O	2834	2835	)	)	)	O
O	2836	2839	may	may	MD	B-VP
O	2840	2842	be	be	VB	I-VP
O	2843	2855	particularly	particularly	RB	B-ADJP
O	2856	2865	effective	effective	JJ	I-ADJP
O	2866	2868	in	in	IN	B-PP
O	2869	2874	these	these	DT	B-NP
B-Cancer	2875	2880	tumor	tumor	NN	I-NP
O	2881	2886	types	type	NNS	I-NP
O	2886	2887	.	.	.	O

